As part of our process to provide safe, quality, effective products, AlloSource is currently conducting a patient study titled A Prospective, Multi-Center Study Evaluating ProChondrix® CR for the Repair of Focal Articular Cartilage Defects in the Knee. Please visit this site for results as they are available.

ProChondrix® Showing Positive Early Clinical Results – 12 Month Prospective Case Series1

A group of 10 patients underwent treatment for an isolated, symptomatic articular cartilage surface lesion. Data collection was performed pre-operatively as well as at 6 and 12 months post-operatively.1
At a mean follow up of 12 months (3-15 months), a statistically significant increase was seen in KOOS Symptoms (+15.97, p=.06), KOOS Function-Daily Living (+28.5, p=.02), KOOS Function-Sports and Recreational Activities (+42.38, p=.004), KOOS Pain (+31.49, p=.0006) and KOOS QOL (+43.51, p=.00008). A statistically significant improvement from baseline was also seen in SF-36 Physical Functioning (+34, p=.05) and SF-36 Bodily Pain (+48.87, p=.009). VAS decreased from 68 to 18.9 (p=.0002). Subjective IKDC scores increased from 35.76 to 56.16 (p=.04). No early failures or re-operations were recorded.1



1. Mehta V. Clinical results of a novel fresh cartilage allograft for focal articular cartilage defects. Poster presented at: International Cartilage Repair Society 13th World Congress; 2016 Sept 24-27; Sorrento, Italy.